Drugs / Utideron
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06636981 | Nov 2024 → Sep 2029 expected | triple-negative breast carcinoma | Fudan University | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Utideron | “Utideron 40mg/m2 D1-5 intravenous infusions, 1 course of treatment every 21 days” NCT06636981 ↗ |
| Route | Intravenous | “Utideron 40mg/m2 D1-5 intravenous infusions” NCT06636981 ↗ |